fda warning letters glp-1 october 2025 news Drug Recalls and Warnings: Recalls for Compounded Semaglutide and Tirzepatide, Wegovy; Facility FDA Issues Warning Letters to

Gastroenterology 130 (1), 4454

Kolligs et al ., 1995)

Mitch Biermann, an internal and obesity medicine specialist at San Diegos Scripps Clinic

LY2189265, a longacting glucagonlike peptide1 analogue, showed a dosedependent effect on insulin secretion in healthy subjects

Berberine also modulates gut microbiota composition, increasing populations of bacteria that produce short-chain fatty acids like butyrate, which in turn stimulate GLP-1 release

Any decision to stop or reduce GLP-1 therapy should be made collaboratively with your healthcare team, with appropriate monitoring arrangements in place to safeguard your metabolic health